NeuroMetrix (NASDAQ:NURO) Earning Somewhat Favorable Media Coverage, Study Finds

Headlines about NeuroMetrix (NASDAQ:NURO) have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. NeuroMetrix earned a daily sentiment score of 0.13 on Accern’s scale. Accern also gave media headlines about the medical device company an impact score of 44.9563779374953 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Separately, HC Wainwright reissued a “buy” rating and issued a $3.00 target price (down previously from $10.00) on shares of NeuroMetrix in a report on Friday, October 20th.

Shares of NeuroMetrix (NASDAQ:NURO) traded down $0.09 during mid-day trading on Wednesday, hitting $1.56. The company’s stock had a trading volume of 107,603 shares, compared to its average volume of 83,048. NeuroMetrix has a 12 month low of $1.52 and a 12 month high of $9.60.

TRADEMARK VIOLATION NOTICE: This news story was first published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of U.S. & international copyright law. The legal version of this news story can be read at https://ledgergazette.com/2017/12/07/neurometrix-nuro-receives-daily-media-impact-rating-of-0-13.html.

NeuroMetrix Company Profile

NeuroMetrix, Inc is a healthcare company combining bioelectrical and digital medicine to address chronic health conditions, including chronic pain, sleep disorders and diabetes. The Company is engaged in the sale of medical equipment, and consumables and accessories. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests.

Insider Buying and Selling by Quarter for NeuroMetrix (NASDAQ:NURO)

Receive News & Ratings for NeuroMetrix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroMetrix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply